Have a feature idea you'd love to see implemented?
Let us know!
VTGN VistaGen Therapeutics Inc
Price (delayed)
$2.53
Market cap
$70.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.24
Enterprise value
-$12.01M
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and
Highlights
VistaGen Therapeutics's EPS has soared by 74% YoY and by 16% from the previous quarter
The company's debt fell by 25% YoY and by 10% QoQ
The equity has soared by 161% YoY but it has decreased by 11% QoQ
VistaGen Therapeutics's revenue has decreased by 10% QoQ but it has increased by 8% YoY
VTGN's quick ratio is down by 25% since the previous quarter
The net income has declined by 19% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of VTGN
Market
Valuations
Earnings
Shares outstanding
27.84M
Market cap
$70.44M
Enterprise value
-$12.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.74
Price to sales (P/S)
88.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-13.71
Revenue
$875,700
EBIT
-$39.56M
EBITDA
-$38.96M
Free cash flow
-$33.65M
Per share
Balance sheet
Liquidity
EPS
-$1.24
Free cash flow per share
-$1.1
Book value per share
$3.44
Revenue per share
$0.03
TBVPS
$3.35
Total assets
$102.5M
Total liabilities
$9.52M
Debt
$1.79M
Equity
$92.97M
Working capital
$92.43M
Debt to equity
0.02
Current ratio
13.29
Quick ratio
12.97
Net debt/EBITDA
2.12
Margins
Efficiency
Dividend
EBITDA margin
-4,448.9%
Gross margin
100%
Net margin
-4,518.1%
Operating margin
-5,207.4%
Return on assets
-33.6%
Return on equity
-36.4%
Return on invested capital
-688.3%
Return on capital employed
-41.7%
Return on sales
-4,517.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTGN stock price
How has the VistaGen Therapeutics stock price performed over time
Intraday
-3.07%
1 week
-7.33%
1 month
-15.67%
1 year
-22.63%
YTD
-50.78%
QTD
-15.95%
Financial performance
How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$875,700
Gross profit
$875,700
Operating income
-$45.6M
Net income
-$39.57M
Gross margin
100%
Net margin
-4,518.1%
The company's net margin fell by 32% QoQ and by 3.2% YoY
The operating margin is down by 32% since the previous quarter and by 18% year-on-year
The company's operating income fell by 27% YoY and by 20% QoQ
The net income has declined by 19% since the previous quarter and by 12% year-on-year
Growth
What is VistaGen Therapeutics's growth rate over time
Valuation
What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
88.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-13.71
VistaGen Therapeutics's EPS has soared by 74% YoY and by 16% from the previous quarter
The equity has soared by 161% YoY but it has decreased by 11% QoQ
The price to book (P/B) is 78% lower than the 5-year quarterly average of 3.3 and 26% lower than the last 4 quarters average of 1.0
The price to sales (P/S) is 22% lower than the last 4 quarters average of 114.0
VistaGen Therapeutics's revenue has decreased by 10% QoQ but it has increased by 8% YoY
Efficiency
How efficient is VistaGen Therapeutics business performance
The ROE has soared by 81% YoY but it has decreased by 3.7% from the previous quarter
The company's return on assets has surged by 74% YoY but it fell by 4% QoQ
VistaGen Therapeutics's ROS has decreased by 32% from the previous quarter and by 3.2% YoY
The company's return on invested capital rose by 28% YoY and by 25% QoQ
Dividends
What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTGN.
Financial health
How did VistaGen Therapeutics financials performed over time
The total assets has soared by 143% YoY but it has contracted by 10% from the previous quarter
The total liabilities is up by 45% year-on-year and by 9% since the previous quarter
The company's debt is 98% lower than its equity
The equity has soared by 161% YoY but it has decreased by 11% QoQ
VTGN's debt to equity has dropped by 71% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.